Prostaglandin Analogue Latanoprost Indicated as Glaucoma Treatment

Prostaglandin Analogue Latanoprost Indicated as Glaucoma Treatment

As the most commonly prescribed treatment for glaucoma, Latanoprost has taken the pharmaceutical headlines by storm with the latest study data revelations. At the end of December 2014 The Lancet published remarkable study results indicating that the use of Latanoprost reduced the risk of glaucoma by over 50 percent when taken for two years’ time. This exciting information proves to pharmacists, practitioners and patients that the value of treatment with this common prostaglandin analogue is far reaching. While medication has been dispensed worldwide for several decades to patients at risk of vision loss due to glaucoma, the protective effect on vision was not established until now. Open-Angle Glaucoma, known also as OAG is the condition for which the vast majority of patients receive treatment with Latanoprost. Roughly 45 million people worldwide are currently diagnosed with OAG, and this number is projected to be 80 million people by the year 2040.

The aforementioned study results were disseminated from the United Kingdom Glaucoma Treatment Study, and included approximately 516 previously untreated patients with new diagnoses of OAG. Half of the patients studied randomly received a daily dose of Latanoprost 0.005% eye drops, and the other half of the trial participants were given a placebo drop. The participants were actively followed for two years’ time and patients were frequently evaluated for glaucoma deterioration. Statistically, the patients who were administered the daily dosage of Latanoprost showed greater than 50 percent less vision deteriorations compared to the placebo group. The most important finding for researchers was that results of this significant vision stabilization were seen in patients who were administered Latanoprost after only one years’ time. Clearly, additional studies are needed for greater lengths of time, such as three to five years to glean very long term data on the positive effects of Latanoprost, which researchers at the NIHR Biomedical Research Centre at Moorfields Eye Hospital plan to do. LGM Pharma can assist clients as a supplier/distributor of the API Latanoprost, CAS# 130209-82-4 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service